Kayyem Jon Faiz, a director at Inhibrx Biosciences, Inc. (INBX), bought $500,000 of company stock on September 23rd, 2026.
The purchase covered 5,000 shares. The reported price range runs from $100 to $100, so the entire block cleared at a single, round number rather than across a ladder of fills. It arrived in one filing, not a string of them.
Round-number executions like this usually mean a block trade or a limit order sitting at a specific level, and they make the arithmetic easy to check. Whatever the mechanics, the cash left the buyer's account on the date of record.
On size, $500,000 is a real personal commitment but a small figure next to the company itself, which carries a market capitalization of about $1.47 billion. A purchase of this scale does not move the float. It does tell you what one board member was willing to pay on a specific day.
The other side of the ledger is the count. Our tables show a single filing behind this total, which means there is no cluster here, no second director following on, and no repeated adding over successive sessions. One person, one trade. Read against a board rather than a crowd, the signal is narrower than a group buy would be, and nothing in the filing speaks to motive.
The price context is close to flat. Inhibrx Biosciences last traded at $99.61, just under the $100 the director paid, so the stock has not run away from the purchase and the buyer is not yet sitting on a visible gain. Anyone measuring the trade against the tape is measuring it against a level the market is still hovering around. For a name in biological products (no diagnostic substances), where clinical news tends to reprice shares in steps rather than drifts, that proximity may not last long in either direction.
Figures in this article come from Form 4 disclosures collected in our own tables and reconciled against the last reported trade price.
Track every Form 4 filed at Inhibrx Biosciences, Inc. (INBX) → insiderbuying.com/companies/INBX